Recent Blog Posts
Walter, John Eddie and Me
Some trials matter more than others. Some verdicts impact perceived values and influence ongoing negotiations. After all, it is the uncertainty of outcome that makes the civil justice system work. Uncertainty creates leverage for both sides and allows the market to set values rather than some inexplicable arbitrary number set by a legislature. Sometimes… Read More »
Mass Torts: Where Have All The Opt Outs Gone?
Every summer I whacks nostalgic about Friday Mountain Boys Camp in Driftwood, Texas. It was my summer camp for 7 years during the late sixties to early seventies. I remember Harry Golightly, the archery instructor, playing his guitar around the campfire singing, “Where have all the flowers gone…” Where indeed, where have all the… Read More »
It’s Football Season: Coaching for the New Associate
The concept of mentoring in the late 80’s went something like this: If you screw up, your colleagues will make like chickens pecking at a sore and take you down. This was before kids got trophies just for participating. As we enter football season and the undeniable wisdom real contact can offer, here are… Read More »
Mailbox Money
Few things satisfy like going to the mailbox and finding that unexpected check. As lawyers, we are in the business of dispensing justice, but we have to keep the lights on in the meantime. Spending meaningful time honing the craft of trial practice is a means towards an end. That end should be creating… Read More »
Stay In The Arena
Of all the unsolicited advice Megyn Kelly should have received, the first should have been STAY IN THE ARENA. Don’t take a two week vacation. Yes, you are a big deal on a big stage. Don’t show any weakness. Who cares if someone doesn’t like your questions. You have a right to seek the… Read More »
Mass Torts
The Winter AAJ conference provided terrific insight into the status of a number of high profile litigations. Risperdal cases involving patients suffering gynecomastia proved successful after a Philadelphia jury awarded a plaintiff $2.5 million in the first trial involving that product. Emerging litigation involving Xarelto and Zofran find themselves well positioned to be successful… Read More »
